Company intelligence / Profile preview

Gefaldiet Service

Acerra, Napoli, Italy

Ownership: Private
Development stage: Other

Overview

Clinical research using Gefaldiet's products, such as Amin 21 K and Nepisond, has shown that very low-calorie ketogenic diets (VLCKD) and protein-based enteral treatments are effective in treating severe obesity and metabolic syndrome. Results typically include significant reductions in BMI, waist circumference, and visceral fat, alongside improvements in glycemic control and lipid profiles.

Therapeutic areas: EndocrinologyNephrologyCardiovascularMetabolic Disorders
Modalities: PeptidesProteinSmall molecule
Industry: Food & Nutrition

Partnerships

GE.FO. Nutrition

Beyond the preview

Go deeper on Gefaldiet Service.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gefaldiet Service.

Explore the full profile